Back to results
US 10,385,027 B2Granted
Triazole derivatives and their use as PDE4 activators
AssigneeMironid Limited
InventorJulia Adam
Life of this patent
Estimating the term…
Abstract
Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes, are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) are also described.
Claims14
A compound of Formula 1:
- wherein
- R1 is selected from H, (C1-4)alkyl and (C1-4)alkyloxy, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros;
- R2 and R6 are independently selected from H, (C1-4)alkyl, (C1-4)alkyloxy, CN and halogen, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros;
- R3, R4 and R5 are independently selected from H, (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkylsulfonyl, C(O)—NR16R17, C(O)—OR16, S(O)2—NR16R17, CN and halogen, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros;
- R7, R8, R10 and R11 are independently selected from H and F;
- R9 is selected from H, (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkylsulfonyl, C(O)—NR16R17, C(O)—OR16, S(O)2—NR16R17, CN and halogen, the (C1-4)alkyl and (C1-4)alkyloxy groups being optionally substituted with 1 to 3 fluoros;
- R12, R13, R14 and R15 are independently selected from H and (C1-4)alkyl;
- each R16 and R17, when present, is independently selected from H and (C1-4)alkyl;
- or a pharmaceutically acceptable salt thereof.
6 more elements
Dependencies are inferred from the claim text.